Target dornase alfa therapy in adults with cystic fibrosis
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
1998 |
---|---|
Erschienen: |
1998 |
Enthalten in: |
Zur Gesamtaufnahme - volume:179 |
---|---|
Enthalten in: |
PharmacoEconomics & outcomes news - 179(1998), 1 vom: Sept., Seite 5-5 |
Sprache: |
Englisch |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Cystic Fibrosis |
doi: |
10.1007/BF03295995 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR033401063 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR033401063 | ||
003 | DE-627 | ||
005 | 20230519071612.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s1998 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/BF03295995 |2 doi | |
035 | |a (DE-627)SPR033401063 | ||
035 | |a (SPR)BF03295995-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 070 |a 610 |q ASE |
084 | |a 44.40 |2 bkl | ||
245 | 1 | 0 | |a Target dornase alfa therapy in adults with cystic fibrosis |
264 | 1 | |c 1998 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
650 | 4 | |a Cystic Fibrosis |7 (dpeaa)DE-He213 | |
650 | 4 | |a National Health Service |7 (dpeaa)DE-He213 | |
650 | 4 | |a Forced Vital Capacity |7 (dpeaa)DE-He213 | |
650 | 4 | |a Cystic Fibrosis Patient |7 (dpeaa)DE-He213 | |
650 | 4 | |a Patient Selection Criterion |7 (dpeaa)DE-He213 | |
773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics & outcomes news |d [Cham] : Springer Nature Switzerland, 1996 |g 179(1998), 1 vom: Sept., Seite 5-5 |w (DE-627)SPR033353808 |w (DE-600)2159696-7 |x 1179-2043 |7 nnns |
773 | 1 | 8 | |g volume:179 |g year:1998 |g number:1 |g month:09 |g pages:5-5 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF03295995 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
912 | |a SSG-OPC-ASE | ||
936 | b | k | |a 44.40 |q ASE |
951 | |a AR | ||
952 | |d 179 |j 1998 |e 1 |c 09 |h 5-5 |